Steve White

Steve White

Auto-generated profile, based on publicly available information

Steve White

Department of HPB and Transplant Surgery, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
CDCinthia B. Drachenberg
Cinthia B. Drachenberg
MBMaike Julia Büttner-Herold
Maike Julia Büttner-Herold
PVPedro Ventura-Aguiar
Pedro Ventura-Aguiar
CHCatherine Horsfield
Catherine Horsfield
AMAlexei V. Mikhailov
Alexei V. Mikhailov
JOJon Odorico
Jon Odorico
The Banff pancreas working schema for diagnosis and grading of rejection is widely used for treatment guidance and risk stratification in centers that perform pancreas allograft biopsies. Since the last update, various studies have provided additional insight regarding the application of the schema and enhanced our understanding of additional clinicopathological entities. This update aims to clarify terminology and lesion description for T-cell mediated and antibody mediated allograft rejections, in both active and chronic forms. In addition, morphological and immunohistochemical tools are described to help distinguish rejection from non-rejection pathologies. For the first time, a clinicopathological approach to islet pathology in the early and late post-transplant periods is discussed. This update also includes a discussion and recommendations on the utilization of endoscopic duodenal donor cuff biopsies as surrogates for pancreas biopsies in various clinical settings. Finally, an analysis and recommendations on the use of donor derived cell free DNA for monitoring pancreas graft recipients is provided. This multidisciplinary effort assesses the current role of pancreas allograft biopsies, and offers practical guidelines that can be helpful to pancreas transplant practitioners as well as experienced pathologists and pathologists in training.

9 December 2023 in HPB
Verified
Journal Article
Open access
ZFZhi Ven Fong
Zhi Ven Fong
GSGeorge Severs
George Severs
JMJohn Moir
John Moir
SWSteve White
Steve White
Motaz QadanMotaz Qadan
Motaz Qadan
STSamuel Tingle
Samuel Tingle
Repurposing existing drugs for use in oncology is more efficient, cost-effective and safe than novel drug discovery. Calcium signalling is increasingly recognised to have a key role in chemoresistance. This study assessed the impact of calcium channel blockers (CCB) in pancreatic cancer. Retrospective population study of patients undergoing resection (curative intent) of pancreatic ductal adenocarcinoma (SEER-Medicare, 2007-2017). Cox models were built to assess the impact on overall survival. As laboratory studies suggest a chemosensitising effect, the impact of CCB was assessed separately in patients receiving neoadjuvant chemotherapy. 6,223 patients were included, of whom 660 were prescribed CCB. In total, 591 received neoadjuvant chemotherapy; in this cohort CCB prescription was associated with improved overall survival when adjusting for multiple prognostic factors (aHR = 0.715, 0.514-0.996, P = 0.047). This effect was not observed in patients not receiving neoadjuvant chemotherapy (aHR = 1.082, 0.982-1.191, P = 0.112). CCB prescription was associated with improved overall survival in patients receiving neoadjuvant chemotherapy prior to pancreatic cancer resection. The association was specific to the group of patients receiving neoadjuvant chemotherapy, mirroring the chemosensitising effect in laboratory studies. This defines patients receiving neoadjuvant chemotherapy as a target population for prospective clinical trials of CCB in pancreatic cancer.


1 May 2021 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
SKSivesh Kamarajah
Sivesh Kamarajah
JBJames R. Bundred
James R. Bundred
Derek ManasDerek Manas
Derek Manas
SWSteven A. White
Steven A. White
Induction immunosuppression for simultaneous pancreas-kidney transplant has helped reduce graft loss due to early rejection. Both thymoglobulin and interleukin 2 receptor antagonists are the most commonly used induction agents; however, some high-volume centers prefer alemtuzumab.Thisnetwork meta-analysis aimedto compare differentinductionregimens for simultaneouspancreaskidney transplantin terms ofbothpancreas and patient graft survival, as well to assess acute rejection. A systematic review was conducted to identify randomized clinical trials up to October 31, 2019, that examined induction regimens for simultaneous pancreas-kidney transplant. Study characteristics, postoperative data (patient, pancreas, and kidney graft survival), complications (eg, bleeding), infection rates, and malignancy rates were extracted. We compared all regimens using randomeffects network meta-analyses to maintain randomization within trials. This study identified 7 randomized clinical trials that involved 536 patients, which reported 5 induction regimens. These regimens included antithymocyte globulin (97 patients), alemtuzumab (42 patients), 2 doses (113 patients) or 5 doses (164 patients) of daclizumab, and no induction therapy (120 patients). In the network meta-analysis, a regimen with 2 doses of daclizumab was consistently ranked first for patient survival and kidney and pancreas graft survival. In contrast, alemtuzumab was ranked best for acute rejection (both pancreas and kidney). Rates of majorinfection (ie, cytomegalovirus) and malignancy were reported in 3 studies, precluding a reliable analysis. Daclizumab with 2 doses, given before simultaneous pancreas-kidney transplant, was associated with the best rates of patient and graft survival. Despite the recent withdrawal of daclizumab, an alternative anti-interleukin 2 induction regimen (basiliximab) has demonstrated promising results in nonrandomized series, warranting that further highquality large-scale randomized clinical trials are still needed.

23 May 2023 in HPB
Verified
Journal Article
Closed access
FRFrancis P. Robertson
Francis P. Robertson
WLWei Lim
Wei Lim
BRBathiya Ratnayake
Bathiya Ratnayake
DADhya Al-Leswas
Dhya Al-Leswas
JSJames Shaw
James Shaw
Sanjay PandanaboyanaSanjay Pandanaboyana
Sanjay Pandanaboyana

14 January 2025 in HPB
Verified
Journal Article
Closed access
NHNing X. Ho
Ning X. Ho
STSamuel J. Tingle
Samuel J. Tingle
GKGeorgios Kourounis
Georgios Kourounis
BMBalaji Mahendran
Balaji Mahendran
RBRebecca Bramley
Rebecca Bramley
CWColin Wilson
Colin Wilson